<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31348">Capecitabine</z:chebi> has shown significant antitumor activity against <z:chebi fb="0" ids="48120">anthracycline</z:chebi>/<z:chebi fb="0" ids="36064">taxane</z:chebi> refractory <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and advanced colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The main drug-related adverse effects are palmar-plantar erythrodysesthesia (<z:e sem="disease" ids="C0549410" disease_type="Disease or Syndrome" abbrv="">hand-foot syndrome</z:e>), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> and <z:hpo ids='HP_0010280'>stomatitis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidemia</z:e> is a rare but important side effect of this drug </plain></SENT>
<SENT sid="3" pm="."><plain>The mechanism of <z:chebi fb="0" ids="31348">capecitabine</z:chebi>-induced <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo> (CI-HTG) is unclear </plain></SENT>
<SENT sid="4" pm="."><plain>It may be due to the decreased activities of <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> lipase and hepatic <z:chebi fb="0" ids="17855">triglyceride</z:chebi> lipase </plain></SENT>
<SENT sid="5" pm="."><plain>This report is associated with 2 patients who developed severe HTG when receiving <z:chebi fb="0" ids="31348">capecitabine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="31348">Capecitabine</z:chebi> was discountinued and <z:chebi fb="0" ids="35679">antilipemic</z:chebi> treatments were given and both cases are in follow-up with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="23" ids="18059">lipid</z:chebi> levels </plain></SENT>
<SENT sid="7" pm="."><plain>This report describes CI-HTG and possible pathogenetic mechanisms and the literature is reviewed </plain></SENT>
</text></document>